Osaka University spin-off: compact, high-sensitivity POCT platform based on GLEIA immunological technology.
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Funding round Immunosens raised an unquantified round (equity and debt) with Shimadzu Future Innovation Fund, Kansai Mirai Venture Fund, SMBC VC and bank loans. | — |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.